



# Neurosteroid Binding Sites and Actions on GABA<sub>A</sub> Receptors

International Society of Anesthetic Pharmacology  
New Orleans, Louisiana  
October 21, 2022

**Alex S. Evers, M.D.**

Henry E. Mallinckrodt Professor of Anesthesiology  
Professor of Developmental Biology (Pharmacology) and Internal Medicine  
Washington University in St. Louis

**Disclosures:** I receive research and educational funding from the:

National Institutes of Health:(R01GM108799, P50MH122379, T32GM108539)  
The Taylor Family Foundation for Innovative Psychiatry


# What are neurosteroids?

Neurosteroids are steroids synthesized within the brain that modulate neuronal excitability by rapid non-genomic actions


Endogenous steroids that modulate CNS behavior

- *Mood*, neuroprotection, excitability

Therapeutically used as *i.v.* ***anesthetics***, anti-depressants and anti-epileptics



# Clinically used steroid anesthetics



Alphaxolone


1971-1985

- **Althesin-** Alphaxolone/Alphadolone in Cremophor EL
- The most widely used i.v. anesthetic in Europe/Canada
- Minimal adverse effects on CV or respiratory
- Histamine reactions/anaphylaxis due to Cremophor
- Withdrawn from Canada and Europe in early 1980's

## Therapeutic indices



	Mice	Rats
Hydroxydione	17.3	-----
Althesin	30.6	28.7
Pregnanolone	-----	40.0
Thiopental	6.9	4.6
Propofol	-----	5.1
Midazolam	-----	6.8

# Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether- $\beta$ -Cyclodextrin



$R=(H)_{21-n}$  or  $(CH_2CH_2CH_2CH_2SO_2ONa)_n$   
where  $n=6.2$  to  $6.9$

## 7-sulfobutyl-ether- $\beta$ -cyclodextrin




**Table 1. Doses Causing Loss of Righting Reflex and Tail Pinch Responses and Lethality Plus Recovery Rates for 2 Alphaxalone Preparations (PHAX and ALTH) and Propofol (PROP)**

	ALTH	PHAX	PROP
Minimal anesthetic dose causing all rats in a group of 10 to lose righting reflex, mg/kg	5	5	10
ED <sub>50</sub> dose for loss of righting reflex, mg/kg mean (95% CI)	3.0 (2.4–4.5)	2.8 (2.2–4.3)	4.6 (3.8–5)
ED <sub>50</sub> dose for loss of tail pinch response, mg/kg mean (95% CI)	6.5 (4.7–8.4)	6.6 (5–8.3)	8.4 (6.7–10.4)
LD <sub>50</sub> , mg/kg mean (95% CI)	43.6 (40.7–46.6)	>84	27.7 (26.3–29)
Duration of loss of righting reflex after minimal anesthetic dose that caused all 10 rats to lose righting reflex, minutes mean (95% CI)	2.8 (1.8–3.8) <sup>a</sup>	2.2 (1.6–2.8) <sup>a</sup>	2.8 (2.1–3.6) <sup>a</sup>
Time (minutes) to complete recovery of rotarod Performance after minimal anesthetic dose (all 10 rats lost righting reflex), mean (95% CI)	19.9 (17.1–22.7) <sup>b</sup>	17 (15.4–18.5) <sup>b</sup>	16 (14.6–17.3) <sup>b</sup>

# Neurosteroid (NS) actions on GABA<sub>A</sub>R

- ✓ Neurosteroids are endogenous modulators of neuronal excitability and nervous system development
- ✓ GABA<sub>A</sub>Rs are the primary molecular targets of neurosteroid action
- ✓ Neurosteroid enhancement of GABA<sub>A</sub> currents is the primary mechanism of anesthetic action

✓ Positive allosteric modulators (PAMs):  
**Allopregnanolone**  
Tetrahydrodeoxycorticosterone (THDOC)




Neil Harrison, Mike Simmonds, Jeff Barker


# Neurosteroid (NS) actions on GABA<sub>A</sub>R

- ✓ Neurosteroids are endogenous modulators of neuronal excitability and nervous system development
- ✓ GABA<sub>A</sub>Rs are the primary molecular targets of neurosteroid action
- ✓ **Neurosteroid enhancement of GABAA currents is the primary mechanism of anesthetic action**


- ✓ **Negative allosteric modulators (NAMs):**  
Pregnenolone sulfate (PS)  
Epi-Allopregnanolone




Epi-Allopregnanolone



Pregnenolone sulfate




Wang M et. al. (2002) J Neurosci.




Akk, G




# Pentameric Ligand-gated ion Channels: Targets of Anesthetic Action




GABA  
Glycine  
Acetylcholine  
Serotonin




Anionic Phospholipids  
**Cholesterol**  
Polyunsaturated Fatty Acids  
**Neurosteroids**





# Sites identified by mutagenesis




Potentiation





Direct activation



# Neurosteroid binding to GLIC-GABA<sub>A</sub> chimera



GLIC-a1GABA<sub>A</sub>R




# Photoaffinity labeling to identify neurosteroid binding sites




Doug Covey, PhD



Allo pregnanolone





KK123



KK200






# Mass spectrometric analysis of pLGICs






# Neurosteroid binding to ELIC- $\alpha$ 1 Chimera



Yusuke Sugasawa,  
MD PhD





# Two neurosteroid binding sites per $\alpha 1$ Subunit



Yusuke Sugasawa,  
MD PhD





ZiWei Chen, MD PhD



# Specific NS binding sites





# Both inter- and $\alpha_1$ intra-subunit sites contribute to neurosteroid potentiation of GABA<sub>A</sub> receptors


ZiWei Chen, MD PhD






Gustav Akk, PhD


# Allopregnanolone binding at $\beta_3$ intrasubunit site inhibits GABA<sub>A</sub>-R



A




B




# Allopregnanolone binding at $\beta_3$ intrasubunit site inhibits GABA<sub>A</sub>-R: $\beta_3$ -homomeric receptors

$\beta_3$  intrasubunit site




Allopregnanolone






WT  $\beta_3$  receptor

Allopregnanolone



B<sub>3</sub> Y284F receptor





Unpublished





# Pregnanolone binds to $\beta_3$ - $\beta_3$ intersubunit site



Gustav Akk, PhD



WT  $\beta_3$  receptor

$\beta_3$  F301S receptor

$\beta_3$  Y284F receptor












Unpublished



# Where does epi-allopregnanolone ( $3\beta$ ) bind?


Yusuke  
Sugasawa, MD  
PhD






**MQ290**

# Neurosteroid binding affinity: A FRET- based binding assay





Hiroki Tateiwa MD, PhD  
Murthy Chintala, PhD




$\alpha_1(\text{Q241L})\beta_3$

Unpublished




MQ290

# Neurosteroid Binding Affinity: A FRET- based binding assay




Hiroki Tateiwa MD, PhD  
Murthy Chintala, PhD





Unpublished

# MQ290 FRET-based binding assay (ELIC- $\alpha$ 1)



Hiroki Tateiwa MD, PhD  
Murthy Chintala, PhD







Unpublished

# Inhibition of MQ290 FRET




Hiroki Tateiwa MD, PhD  
Murthy Chintala, PhD








Unpublished

# PAM-neurosteroid inhibition of MQ290 FRET



Hiroki Tateiwa MD, PhD  
Murthy Chintala, PhD




Unpublished


# NAM-neurosteroid potentiation of GABA<sub>A</sub>R ( $\alpha_1\beta_3$ )




Hiroki Tateiwa, MD, PhD  
Ganesan Arulkumaran, PhD  
Murthy Chintala, PhD





Epi-Allopregnanolone



Epi-Pregnanolone



Epi-Ganaxolone



Unpublished

	<b>IC<sub>50</sub></b> ( $\mu\text{M}$ , $\pm$ SEM)	<b>Hill Slope</b> ( $\pm$ SEM)	<b>K<sub>i</sub></b> ( $\mu\text{M}$ , $\pm$ SEM)
<b>3<math>\alpha</math>-NS: Intersubunit Site</b>			
AlloP	0.19 $\pm$ 0.02	-1.84 $\pm$ 0.28	<b>0.08 <math>\pm</math> 0.01</b>
Preg	0.70 $\pm$ 0.09	-1.30 $\pm$ 0.20	<b>0.31 <math>\pm</math> 0.04</b>
GX	0.28 $\pm$ 0.03	-1.57 $\pm$ 0.23	0.12 $\pm$ 0.01
YX03	1.11 $\pm$ 0.17	-1.38 $\pm$ 0.28	<b>0.48 <math>\pm</math> 0.08</b>
<b>3<math>\beta</math>-NS: Intrasubunit Site</b>			
Epi-AlloP	0.69 $\pm$ 0.04	-0.82 $\pm$ 0.32	<b>0.50 <math>\pm</math> 0.03</b>
Epi-Preg	1.81 $\pm$ 0.94	-0.56 $\pm$ 0.16	<b>1.31 <math>\pm</math> 0.68</b>
Epi-GX	1.35 $\pm$ 0.38	-1.22 $\pm$ 0.40	0.98 $\pm$ 0.28
YX04	2.62 $\pm$ 3.00	-0.63 $\pm$ 0.38	<b>1.89 <math>\pm</math> 2.17</b>



**Hiroki Tateiwa MD, PhD**  
**Murthy Chintala, PhD**

# Summary

- Neurosteroids bind to multiple sites on the GABA<sub>A</sub> receptor
- Different neurosteroids bind to overlapping subsets of these sites
- Different neurosteroids can be PAMs or NAMs at a given site
- There may be additional neurosteroid binding sites in GABA<sub>A</sub> receptors with different subunit composition and cyclic order

# Conclusions

- The matrix of multiple endogenous neurosteroids bathing GABA<sub>A</sub> receptors and the array of subunit compositions expressed with cellular and anatomic specificity indicates a **complex endogenous pharmacology in which neurosteroids fine tune neuronal excitability and regulate behavior (mood)**
- The structural complexity of neurosteroids and (and their binding sites) presents an opportunity to develop neurosteroid analogues that are **site-specific agonists and antagonists** for fine-tuning sedation, anesthesia and mood

## Evers Lab

ZiWei Chen  
Hiroki Tateiwa  
Wayland Cheng  
Yusuke Sugasawa  
Melissa Budelier  
John Bracamontes  
Lei Wang  
Satyanarayna Chintala  
Fatima Amtashar

## Doug F. Covey Lab

Katherisan Krishnan  
Ming-xing Qian

## Gustav Akk Lab

Alison Germann  
Spencer Pierce

## David Reichert

Supported by: NIH PO1 GM-47969, NIH  
RO1 GM108799, NIH P50MH122379  
NIH KO8GM126336, NSF DGE-1143954  
and the Taylor Family Institute for  
Innovative Psychiatric Research

# Acknowledgements

